Journal of Medicinal Chemistry · 2014 · 28 citations · 7 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsLead Compound DesignLigand-based DesignPotency OptimizationQuantitative Structure-activity RelationshipsStructure-activity Relationship AnalysisMolecular Property-based DesignOptimization Of Pharmacodynamic PropertiesPharmacokinetic-pharmacodynamic OptimizationProperty-based Drug DesignStructure - Activity Relationship OptimizationStructure - Pharmacokinetic Relationship AnalysisStructure-activity Relationship ModelingStructure-based Ligand Design
Utilizing structure-based drug design, a novel dihydropyridopyrimidinone series which exhibited potent Hsp90 inhibition, good pharmacokinetics upon oral administration, and an excellent pharmacokinetic/pharmacodynamic relationship in vivo was developed from a commercial hit. The exploration of this series led to the selection of NVP-HSP990 as a development candidate.
7
Luke Whitesell, Edward G. Mimnaugh, B. de Costa et al. · Proceedings of the National Academy of Sciences · 1994 · 1.4K citations
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Clinical Cancer Research · 2012 · 903 citations · Full text
Medicine, Oncology, Pharmacology +16